Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8887-8894

  Lu, Tao ^a   Seto, Wai Kay ^a,b   Zhu, Ran Xu ^a   Lai, Ching Lung ^b   Yuen, Man Fung ^b  

^a THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepato cellular carcinoma; Prevention; Vaccination

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ALPHA2B INTERFERON; CYCLIN D1; ENTECAVIR; GINKGO BILOBA EXTRACT; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; MITOGEN ACTIVATED PROTEIN KINASE P38; P21 ACTIVATED KINASE 1; PEGINTERFERON; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROPRANOLOL; PROTEIN KINASE B; RESVERATROL; RIBAVIRIN; SIRTUIN; UNCLASSIFIED DRUG; VIRUS DNA; VITAMIN D;

AGE; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; GENDER; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPOALBUMINEMIA; IRON STORAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); MIXED INFECTION; NONHUMAN; PORTAL HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); VACCINATION; VITAMIN BLOOD LEVEL;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; PREVENTION; VACCINATION;

ANTICARCINOGENIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COINFECTION; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84890904585     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8887     Document Type: Article

References (59)

1. Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013; 35: 111-120 [PMID: 23010890 DOI: 10.1007/s00281-012-0330-z]
2. Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 2013; 102: 74-83 [PMID: 23583669 DOI: 10.1016/j.ygeno]
3. Zemel R, Issachar A, Tur-Kaspa R. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011; 15: 261-279, vii-x [PMID: 21689612 DOI: 10.1016/j.cld.2011.03.001]
4. Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Bio-logics 2012; 6: 207-219 [PMID: 22904613 DOI: 10.2147/BTT. S23907]
5. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepa-tocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011; 21: 401-416 [PMID: 22041528]
6. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218]
7. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-1754 [PMID: 20114048 DOI: 10.1053/j.gastro]
8. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocel-lular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077 [PMID: 18657133 DOI: 10.1111/j.1365-2036.2008.03816.x]
9. Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4258-4270 [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258]
10. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498 [PMID: 15361502]
11. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574 [PMID: 21497551 DOI: 10.1016/ S1470-2045(11)70077-8]
12. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88 [PMID: 18977053 DOI: 10.1016/ j.jhep.2008.07.023]
13. Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Wong VW. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013; 144: 933-944 [PMID: 23415803 DOI: 10.1053/j.gastro.2013.02.002]
14. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-1665 [PMID: 20194845 DOI: 10.1200/JCO.2009.26.2675]
15. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profles. Hepatology 2013; 58: 546-554 [PMID: 23504622 DOI: 10.1002/hep.26385]
16. Effect of interferon-alpha on progression of cirrhosis to he-patocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351: 1535-1539 [PMID: 10326535]
17. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337 [PMID: 23460056 DOI: 10.7326/0003-4819-158-5-201303050-0 0005]
18. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J. Effcacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501 [PMID: 23099187 DOI: 10.1016/j.jhep.2012.10.017]
19. Ueda T, Honda M, Horimoto K, Aburatani S, Saito S, Yamashita T, Sakai Y, Nakamura M, Takatori H, Sunagozaka H, Kaneko S. Gene expression profling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. Genomics 2013; 101: 238-248 [PMID: 23485556 DOI: 10.1016/j.ygeno.2013.02.007]
20. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92: 1159-1164 [PMID: 10904089]
21. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccin-ees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355 [PMID: 19759364 DOI: 10.1093/jnci/djp288]
22. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859 [PMID: 9197213]
23. Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011; 81 Suppl 1: 41-49 [PMID: 22212935 DOI: 10.1159/ 000333258]
24. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond) 2011; 61: 531-540 [PMID: 22114089 DOI: 10.1093/ occmed/kqr136]
25. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol 2012; 55: 296-302 [PMID: 22999800 DOI: 10.1016/ j.jcv.2012.08.022]
26. Smolle E, Zöhrer E, Bettermann K, Haybaeck J. Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing iran and worldwide findings? Hepat Mon 2012; 12: e7879 [PMID: 23233866 DOI: 10.5812/ hepatmon.7879]
27. Lee D, Chung YH, Lee SH, Kim SE, Lee YS, Kim KM, Lim YS, Lee HC, Lee YS, Yu E. Effect of response to interferon-α therapy on the occurrence of hepatocellular carcinoma in patients with chronic hepatitis B. Dig Dis 2012; 30: 568-573 [PMID: 23258096 DOI: 10.1159/000343068]
28. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145 [PMID: 11431745]
29. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57: 399-408 [PMID: 22806323 DOI: 10.1002/hep.25937]
30. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 2009; 24: 1352-1357 [PMID: 19702903 DOI: 10.1111/j.1440-1746.2009.05985.x]
31. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimi-crob Chemother 2011; 66: 2715-2725 [PMID: 21965435 DOI: 10.1093/jac/ dkr388]
32. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL. Long-term lami-vudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12: 1295-1303 [PMID: 18240869]
33. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215]
34. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53: 118-125 [PMID: 20471129 DOI: 10.1016/j.jhep.2010.02.026]
35. Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012; 47: 577-585 [PMID: 22231575 DOI: 10.1007/ s00535-011-0522-7]
36. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology 2013 Feb 6; Epub ahead of print [PMID: 23389810 DOI: 10.1002/ hep.26301]
37. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Jans-sen HL. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-765 [PMID: 22490523 DOI: 10.1136/gutjnl-2012-302024]
38. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Min-gozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, Guidotti LG. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109: E2165-E2172 [PMID: 22753481 DOI: 10.1073/pnas.1209182109]
39. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND, McG-lynn KA. Nonsteroidal anti-infammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012; 104: 1808-1814 [PMID: 23197492 DOI: 10.1093/jnci/ djs452]
40. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-630 [PMID: 22271485 DOI: 10.1200/JCO.2011.36.0917]
41. Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, Tsai TF. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 2012; 5: 952-962 [PMID: 22659145 DOI: 10.1158/1940-6207. CAPR-12-0001]
42. Parekh P, Motiwale L, Naik N, Rao KV. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 2011; 63: 167-173 [PMID: 20133117 DOI: 10.1016/j.etp.2009.11.005]
43. Venturelli S, Berger A, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Schleicher S, Mayer M, Weiss TS, Bischoff SC, Lauer UM, Bitzer M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells. PLoS One 2013; 8: e73097 [PMID: 24023672 DOI: 10.1371/journal.pone.0073097]
44. Wang H, Liu H, Chen K, Xiao J, He K, Zhang J, Xiang G. SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep 2012; 28: 311-318 [PMID: 22552445 DOI: 10.3892/or.2012.1788]
45. Wang WW, Guo JC, Xun YH, Xiao LN, Shi WZ, Shi JP, Lou GQ. The effect of extract of ginkgo biloba leaf during the formation of HBV-related hepatocellular carcinoma. Zhon-ghua Shiyan He Linchuang Bingduxue Zazhi 2011; 25: 325-327 [PMID: 22338214]
46. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacifc region. J Gastroenterol 2013; 48: 681-688 [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9]
47. Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon 2012; 12: e6031 [PMID: 23166535 DOI: 10.5812/hepatmon.6031]
48. Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 2012; 39: 374-383 [PMID: 22846856 DOI: 10.1053/j.seminoncol]
49. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY. Genetic analyses reveal a role for vitamin D insuffciency in HCV-associated hepatocellular carcinoma development. PLoS One 2013; 8: e64053 [PMID: 23734184 DOI: 10.1371/journal.pone.0064053]
50. Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) 2012; 5: 1007-1014 [PMID: 22525582 DOI: 10.1158/1940-6207.CAPR-11-0450]
51. Huang JT, Tseng CP, Liao MH, Lu SC, Yeh WZ, Sakamoto N, Chen CM, Cheng JC. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase. J Virol 2013; 87: 4994-5004 [PMID: 23427160 DOI: 10.1128/JVI.02526-12]
52. Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/ HCV coinfection. Expert Opin Pharmacother 2010; 11: 919-928 [PMID: 20166841 DOI: 10.1517/14656561003637659]
53. Oh JK, Shin HR, Lim MK, Cho H, Kim DI, Jee Y, Yun H, Yoo KY. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer 2012; 12: 452 [PMID: 23039099 DOI: 10.11 86/1471-2407-12-452]
54. Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003; (2): CD002799 [PMID: 12804438]
55. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takachi R, Tanaka Y, Mizokami M, Tsugane S. Consumption of n-3 fatty acids and fsh reduces risk of he-patocellular carcinoma. Gastroenterology 2012; 142: 1468-1475 [PMID: 22342990 DOI: 10.1053/j.gastro.2012.02.018]
56. Weylandt KH, Krause LF, Gomolka B, Chiu CY, Bilal S, Nadolny A, Waechter SF, Fischer A, Rothe M, Kang JX. Suppressed liver tumorigenesis in fat-1 mice with elevated ome-ga-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α. Carcinogenesis 2011; 32: 897-903 [PMID: 21421544 DOI: 10.1093/carcin/bgr049]
57. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyun-saturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 2009; 8: 3046-3055 [PMID: 19887546 DOI: 10.1158/1535-7163.MCT-09-0551]
58. Bridges JF, Joy SM, Gallego G, Kudo M, Ye SL, Han KH, Cheng AL, Blauvelt BM. Needs for hepatocellular carcinoma control policy in the Asia-Pacifc region. Asian Pac J Cancer Prev 2011; 12: 2585-2591 [PMID: 22320959]
59. Kwon H, Lok AS. Does antiviral therapy prevent hepato-cellular carcinoma? Antivir Ther 2011; 16: 787-795 [PMID: 21900710 DOI: 10.3851/IMP1895]